VacV exits stealth with systemic oncolytic viral delivery tech and vision of immune system stimulation

VacV Biotherapeutics has taken early steps toward the validation of its systemically deliverable Vaccinia virus, exiting stealth with $3 million to complete preclinical studies of its cancer immunotherapies.